Meeting
2017 ASCO Annual Meeting
Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses.
Authors
Robin Kate Kelley
University of California, San Francisco, San Francisco, CA
Robin Kate Kelley , Ghassan K. Abou-Alfa , Johanna C. Bendell , Tae-You Kim , Mitesh J. Borad , Wei-Peng Yong , Michael Morse , Yoon-Koo Kang , Marlon Rebelatto , Mallory Makowsky , Feng Xiao , Shannon R. Morris , Bruno Sangro
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT02519348
Citation
J Clin Oncol 35, 2017 (suppl; abstr 4073)
DOI
10.1200/JCO.2017.35.15_suppl.4073
Abstract #
4073
Poster Bd #
65
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Safety and efficacy of durvalumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from the phase 2 study 22 (NCT02519348).
First Author: Ho Yeong Lim
Poster
2016 ASCO Annual Meeting
Phase 1/2 study of durvalumab and tremelimumab as monotherapy and in combination in patients with unresectable hepatocellular carcinoma (HCC).
First Author: Ghassan K. Abou-Alfa
Poster
2024 ASCO Annual Meeting
Phase 2/3 study of livmoniplimab in combination with budigalimab in patients with locally advanced or metastatic hepatocellular carcinoma.
First Author: Ghassan K. Abou-Alfa
Poster
2023 ASCO Annual Meeting
Temporal patterns of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC).
First Author: George Lau